Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

Breast Cancer Conversations: What You Need To Know About Your Metabolic Health and Breast Cancer

What You Need To Know About Your Metabolic Health and Breast Cancer Breast Cancer Conversations is a podcast that discusses all things breast cancer! We share stories of those who have been diagnosed. We interview medical professionals, doctors, radiologists, and oncologists.  We speak with advocates and caregivers. We are your voice! If you have questions, […]

Read More

New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance

SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven (eribulin, Esai). Evexomostat is among the first anti-cancer therapeutics being developed specifically for cancer patients with baseline metabolic dysfunction (obesity, type […]

Read More

Prostate Cancer Research Collaboration with Australia Univ. of Technology, Prof. Colleen Nelson, PhD

QUT SDX Collaboration Press Release 07Dec 2021 – Part of an ongoing investigation focused on how obesity and dysregulated metabolic hormones promote prostate cancer progression and metastasis – Studies aim to quantify the ability of SynDevRx MetAP2 inhibitor evexomostat (SDX-7320) to control tumor growth of castration resistant prostate cancers

Read More

2021 San Antonio Breast Cancer Symposium Poster Presentation (SDX-7320+Capivasertib in Her2+ model)

Read More

SynDevRx Announces Research Collaboration with Maine Medical Center Research Institute to Study the Effects of SDX-7320 In Obesity-Accelerated Multiple Myeloma Models

SynDevRx, Inc., a clinical-stage biotechnology company leading the development of treatments for obesity-accelerated cancers, today announced a research collaboration with Maine Medical Center Research Institute’s Michaela Reagan, PhD. The collaboration will study the role of MetAP2 in obesity-accelerated growth and metastatic potential of multiple myeloma – a form of cancer that develops in bone marrow. […]

Read More

Obesity, Type 2 Diabetes,and Cancer Risk

Obesity and type 2 diabetes have both been associated with increased cancer risk and are becoming increasingly prevalent. Metabolic abnormalities such as insulin resistance and dyslipidemia are associated with both obesity and type 2 diabetes and have been implicated in the obesity-cancer relationship. Multiple mechanisms have been proposed to link obesity and diabetes with cancer […]

Read More

SDX Presents New Oncology Data at 2021 AACR Showing Reversal of Resistance Mechanisms to CDK4/6 Inhibitors

CDK 4/6 inhibitors are an important drug class in 1st line metastatic breast cancer. Unfortunately, resistance inevitably develops and causes treatment failure and the patient’s cancer progresses. Here we show that SDX-7320 overcomes many of the known mechanisms of developed resistance to CDK 4/6 inhibition. 2021 AACR Poster Apr 2021

Read More

Effects of Diet and Exercise induced Weight Loss on Biomarkers of Inflammation in Breast Cancer Survivors

Leptin may be a primary mediator of exercise-induced improvements in breast cancer recurrence.

Read More

Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomisation studies

The opportunity to draw upon genetic data from large-scale, international consortia allows for triangulation of evidence using distinct methodological approaches that make orthogonal underlying assumptions and suffer from distinct sources of bias. The findings of our study support a potential causal effect of genetically predicted T2DM and/or fasting insulin levels, rather than genetically predicted fasting […]

Read More

Cancer replaces vascular disease as leading cause of excess death in diabetes

“We would expect at some point cancer would overtake vascular disease as a leading cause of death, both in the general population and among people with diabetes,” Song told Healio. “What surprises me most is the magnitude of the gap. If you look at the number for total cancer deaths, it is almost twice as […]

Read More